Description

Almitrine Bismesylate & Raubasine combines raubasine, a vasodilator; and almitrine, a respiratory stimulant. Raubasine has a adrenolytic activity which is predominantly related to a post-synaptic blocking effect. Furthermore, under conditions of cerebral hypoxia, almitrine causes an increase in the partial pressure of oxygen in arterial blood (Pa02); almitrine causes an increase in the Pa02 and an increase in the oxygen saturation in arterial blood (Sa02), without modifying ventilatory parameters.

This tablet is contraindicated in patients with hypersensitivity to any of the ingredients of it or severe hepatic impairment.

Weight loss, nausea, sensations of heaviness or burning in the stomach, gastrointestinal disorders, diarrhoea or constipation, insomnia, drowsiness, agitation, anxiety, dizziness, palpitations.

It is not recommended in pregnancy. It should be used with caution only when the expected benefit to the mother is greater than the possible risk to the fetus.

Due to the presence of lactose, this drug should not be used in the case of galactosemia, of glucose and galactose malabsorption syndrome or of lactose deficiency (rare metabolic diseases). Do not exceed the recommended dose.

Signs include tachycardia, arterial hypotension, polypnoea and respiratory alkalosis.

Cerebral vasodilator & Neurosensory oxygenator drugs